1. Scrip
  2. >>Therapy Areas

BioNotebook: Medivation, Clovis, Arena 4Q updates; Abide/Celgene discovery deal; 3 new IPO filers, 2 other set terms

 
• By Mandy Jackson

Medivation, Clovis Oncology and Arena Pharmaceuticals waited until the end of earnings season to provide fourth quarter financial updates and they took a beating on 28 February, which was a tough day for US biotechnology stocks.

Medivation, Clovis Oncology and Arena Pharmaceuticals waited until the end of earnings season to provide fourth quarter financial updates and they took a beating on 28 February, which was a tough day for US biotechnology stocks.

The Nasdaq index closed down just 0.25%, but the Nasdaq Biotechnology Index (NBI) closed down 2.8%. Medivation ended the day...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

PureTech Ponders Way Forward As CEO Exits

 
• By Kevin Grogan

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 
• By Anju Ghangurde

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By Joseph Haas

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.